Stock Movers Novo Up, Orsted Gains, M&S Dips
Nov 5, 2025
Louise Moon, Bloomberg Breaking News editor, shares insights on major market developments. Novo Nordisk is facing challenges, cutting its forecast due to declining sales of its weight-loss drugs. Meanwhile, Orsted aims to calm investors with assurances after a tough quarter and ongoing US project issues. Marks & Spencer is on the rebound, reporting stronger profits despite the setback from a recent cyberattack, with optimistic projections for the second half of the year. Moon’s analysis reveals the critical shifts affecting these companies.
AI Snips
Chapters
Transcript
Episode notes
Novo Nordisk Wrestles With Slower Drug Growth
- Novo Nordisk is facing slowing growth as Wegovy and Ozempic sales lag amid rising competition and slower market expansion.
- The new CEO is cutting staff and pursuing acquisitions to counter competition while US pricing commentary offered some positive support.
Orsted Seeks To Reassure After Weak Quarter
- Orsted confirmed full-year profit guidance to reassure investors after a weak quarter and a large US tariff-related charge.
- The company says its project portfolio is progressing and management aims to signal a return to normality despite US regulatory hurdles.
M&S Beats Estimates Despite Cyberattack Hit
- Marks & Spencer beat first-half profit estimates despite a severe first-quarter hit from a cyberattack that disrupted online sales for months.
- CEO says food is outperforming while fashion and home recover, and second-half profit should at least match last year.